US-Latin American-Caribbean Clinical Trials Network (ULACNet)

Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers (ULACNet)

RFA-CA-18-018: "Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin American-Caribbean Clinical Trials Network: Partnership Centers (U54 Clinical Trial Required)"

The US-Latin American-Caribbean Clinical Trials Network: Partnership Centers, proposed to be established through the funding opportunity RFA-CA-18-018, will focus on improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. This international collaborative network will design, conduct, and complete prevention clinical trials in low- and middle-income countries (LMICs) in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.  Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals.

Each proposed ULACNet Partnership Center will be a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in LMICs in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment. Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. 

This website is designed to help potential applicants find resources related to the RFA in support of ULACNet. For additional information or questions, please email Dr. Vikrant Sahasrabuddhe at sahasrabuddhevv@mail.nih.gov.

Program Information and Resources for Applicants

Pre-Application Webinar Slides

Slides (PDF, 573 kb)

A public pre-application webinar was held Friday, October 12, 2018 at 1:00 pm- 2:00 pm (EDT) to provide information about the FOA to prospective applicants. NCI staff provided an overview of the FOA and the application review process and answered questions from prospective applicants. The webinar was open to all prospective applicants. Participation in this webinar, although encouraged, was optional and was not required for the submission of an application in response to RFA-CA-18-018. Webinar slides are posted here and questions discussed during the webinar are included within the FAQs.

Frequently Asked Questions (FAQs)

Frequently Asked Questions (FAQs) addresses common questions from potential applicants regarding RFA-CA-18-018 and those discussed in the pre-application webinar.

All applicants are encouraged to review the FAQ document prior to submitting their application. We anticipate updating the FAQ document as needed and recommend that applicants check back for updates to the FAQs regularly until their submission date.

Last updated: November 13, 2018

Program Information

Program concept presentation to NCI Board of Scientific Advisors (BSA)

  • Slides (PDF, 518 KB)
     
  • VideoCast (presentation between 00:50:40 and 01:24:10)